Cargando…

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial

BACKGROUND: Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children. METHODS: This phase III open-label randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Johanna M., Sawa, Patrick, Makio, Nicodemus, Omweri, George, Osoti, Victor, Okach, Selpha, Choy, Felix, Schallig, Henk D. F. H., Mens, Pètra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952621/
https://www.ncbi.nlm.nih.gov/pubmed/29764419
http://dx.doi.org/10.1186/s12936-018-2340-3
_version_ 1783323223418470400
author Roth, Johanna M.
Sawa, Patrick
Makio, Nicodemus
Omweri, George
Osoti, Victor
Okach, Selpha
Choy, Felix
Schallig, Henk D. F. H.
Mens, Pètra
author_facet Roth, Johanna M.
Sawa, Patrick
Makio, Nicodemus
Omweri, George
Osoti, Victor
Okach, Selpha
Choy, Felix
Schallig, Henk D. F. H.
Mens, Pètra
author_sort Roth, Johanna M.
collection PubMed
description BACKGROUND: Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children. METHODS: This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed P. falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine–artesunate or artemether–lumefantrine, dosed according to bodyweight, for 3 days. RESULTS: Of 197 participants, 101 received pyronaridine–artesunate and 96 received artemether–lumefantrine. The day-28 adequate clinical and parasitological response in the per-protocol population, PCR-corrected for reinfections, was 98.9% (93/94, 95% CI 94.2–99.8) for pyronaridine–artesunate and 96.4% (81/84, 95% CI 90.0–98.8) for artemether–lumefantrine. Pyronaridine–artesunate was found to be non-inferior to artemether–lumefantrine: the treatment difference was 2.5% (95% CI − 2.8 to 9.0). Adverse events occurred in 41.6% (42/101) and 34.4% (33/96) of patients in the pyronaridine–artesunate group and the artemether–lumefantrine group, respectively. No participants were found to have alanine or aspartate aminotransferase levels > 3 times the upper limit of normal. CONCLUSIONS: Pyronaridine–artesunate was well tolerated, efficacious and non-inferior to artemether–lumefantrine for the treatment of uncomplicated P. falciparum malaria in Kenyan children. Results are in line with previous reports and inclusion of pyronaridine–artesunate in paediatric malaria treatment programmes should be considered. This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https://clinicaltrials.gov/ct2/show/NCT02411994?term=pyronaridine–artesunate&cond=Malaria&cntry=KE&rank=1 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2340-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5952621
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59526212018-05-21 Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial Roth, Johanna M. Sawa, Patrick Makio, Nicodemus Omweri, George Osoti, Victor Okach, Selpha Choy, Felix Schallig, Henk D. F. H. Mens, Pètra Malar J Research BACKGROUND: Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children. METHODS: This phase III open-label randomized controlled non-inferiority trial was conducted in Western Kenya. Children aged 6 months to ≤ 12 years with a bodyweight > 5 kg and microscopically confirmed P. falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine–artesunate or artemether–lumefantrine, dosed according to bodyweight, for 3 days. RESULTS: Of 197 participants, 101 received pyronaridine–artesunate and 96 received artemether–lumefantrine. The day-28 adequate clinical and parasitological response in the per-protocol population, PCR-corrected for reinfections, was 98.9% (93/94, 95% CI 94.2–99.8) for pyronaridine–artesunate and 96.4% (81/84, 95% CI 90.0–98.8) for artemether–lumefantrine. Pyronaridine–artesunate was found to be non-inferior to artemether–lumefantrine: the treatment difference was 2.5% (95% CI − 2.8 to 9.0). Adverse events occurred in 41.6% (42/101) and 34.4% (33/96) of patients in the pyronaridine–artesunate group and the artemether–lumefantrine group, respectively. No participants were found to have alanine or aspartate aminotransferase levels > 3 times the upper limit of normal. CONCLUSIONS: Pyronaridine–artesunate was well tolerated, efficacious and non-inferior to artemether–lumefantrine for the treatment of uncomplicated P. falciparum malaria in Kenyan children. Results are in line with previous reports and inclusion of pyronaridine–artesunate in paediatric malaria treatment programmes should be considered. This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https://clinicaltrials.gov/ct2/show/NCT02411994?term=pyronaridine–artesunate&cond=Malaria&cntry=KE&rank=1 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12936-018-2340-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-15 /pmc/articles/PMC5952621/ /pubmed/29764419 http://dx.doi.org/10.1186/s12936-018-2340-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Roth, Johanna M.
Sawa, Patrick
Makio, Nicodemus
Omweri, George
Osoti, Victor
Okach, Selpha
Choy, Felix
Schallig, Henk D. F. H.
Mens, Pètra
Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title_full Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title_fullStr Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title_full_unstemmed Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title_short Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial
title_sort pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated plasmodium falciparum malaria in kenyan children: a randomized controlled non-inferiority trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952621/
https://www.ncbi.nlm.nih.gov/pubmed/29764419
http://dx.doi.org/10.1186/s12936-018-2340-3
work_keys_str_mv AT rothjohannam pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT sawapatrick pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT makionicodemus pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT omwerigeorge pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT osotivictor pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT okachselpha pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT choyfelix pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT schallighenkdfh pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial
AT menspetra pyronaridineartesunateandartemetherlumefantrineforthetreatmentofuncomplicatedplasmodiumfalciparummalariainkenyanchildrenarandomizedcontrollednoninferioritytrial